Table 1.

Cell cycle phase distribution of HUVECs treated with celecoxib or DMC at the indicated concentrations in 2% fetal bovine serum–supplemented medium for 24 hours

Cells in Cell Cycle Phases (%)
G0-G1SG2-M
DMSO vehicle53.3 ± 4.411.9 ± 0.833.7 ± 5.7
Celecoxib (μmol/L)1062.55 ± 5.79.56 ± 1.924.2 ± 4.7
1564.6 ± 4.09.4 ± 1.722.9 ± 3.0
2065.9 ± 3.98.6 ± 2.022.5 ± 3.0
2569.3 ± 3.86.3 ± 1.622.9 ± 3.2
DMC (μmol/L)1064.3 ± 4.18.5 ± 1.723.4 ± 3.4
1565.2 ± 3.67.8 ± 1.622.9 ± 3.5
2069.7 ± 7.16.1 ± 2.420.8 ± 3.1
2573.2 ± 3.04.2 ± 2.922.1 ± 1.5
Rofecoxib (μmol/L)1053.4 ± 4.010.5 ± 2.832.8 ± 0.7
1552.9 ± 3.211.7 ± 2.033.6 ± 2.7
2054.2 ± 3.710.9 ± 1.734.0 ± 2.3
2554.0 ± 3.211.2 ± 2.834.2 ± 1.8
  • NOTE: Control cells received DMSO vehicle. Each tabulated percentage represents the average of three independent experiments.